Rossari Biotech reported a strong 28.2% revenue jump to ₹697.2 crore in Q1 FY27, driven by its diverse chemical segments. However, EBITDA margins compressed by 90 basis points to 11.6%, impacting overall profitability growth.
Rossari Biotech Reports Strong Revenue Growth in Q1 FY27 Amidst Margin Pressure
Revenue: ₹697.2 crore PAT: ₹35.1 crore Reader Takeaway: Strong revenue growth driven by core segments, but margin compression and flat B2C/Institutional growth need monitoring. ## What just happened Rossari Biotech announced its financial results for the first quarter of FY27 (Q1 FY27). The company achieved a revenue of ₹697.2 crore, marking a significant 28.2% increase year-on-year from ₹543.7 crore in Q1 FY26. This growth was primarily propelled by its Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN) segments. ## Why this matters While the topline showed impressive growth, the company experienced margin compression. The EBITDA margin declined by 90 basis points to 11.6% compared to 12.5% in the previous year's quarter. Consequently, absolute EBITDA rose to ₹80.6 crore from ₹67.9 crore, and Profit After Tax (PAT) saw a modest increase of 4.5% to ₹35.1 crore from ₹33.6 crore. ## The backstory The company's performance is largely supported by its HPPC segment, which accounts for 79% of its revenue. Rossari Biotech has been focusing on expanding its capacity and diversifying its product portfolio. Recently, it commissioned a greenfield blending facility in Thailand with a 5,000 MTPA capacity to cater to Southeast Asian markets, reinforcing its international expansion strategy. ## What changes now Rossari Biotech has embraced an asset-light strategy, evident in the sale of its Andheri office during the quarter. The newly commissioned Thailand facility is expected to boost its presence in Southeast Asia. Investors will be keenly observing how the company manages its margins while pursuing growth, especially in its developing Institutional and B2C segments. ## Risks to watch The primary concerns are the ongoing margin compression, indicated by the 90 bps dip in EBITDA margin, which could signal rising input costs or competitive pricing pressures. Additionally, the flat performance in the Institutional and B2C segments requires close monitoring for future turnaround potential and diversification success. ## Peer comparison While specific peer data for Q1 FY27 is not provided in the filing, Rossari Biotech operates in the specialty chemicals sector, competing with players focused on home, personal care, and textile chemicals. Companies in this space often face similar challenges regarding raw material price volatility and evolving consumer demand. ## Context metrics (time-bound) * **Revenue Growth (YoY):** +28.2% to ₹697.2 crore in Q1 FY27. * **EBITDA Growth (YoY):** +18.7% to ₹80.6 crore in Q1 FY27. * **PAT Growth (YoY):** +4.5% to ₹35.1 crore in Q1 FY27. * **EBITDA Margin:** 11.6% in Q1 FY27 (down from 12.5% in Q1 FY26). ## What to track next Investors should monitor upcoming quarterly results to see if Rossari Biotech can improve its EBITDA margins. Tracking the growth trajectory of the Institutional and B2C segments will be crucial to gauge the success of its diversification efforts. The performance of the new Thailand facility will also be a key factor.
